Zobrazeno 1 - 10
of 28
pro vyhledávání: '"J. Robert Putnak"'
Autor:
Heather Friberg, Luis J. Martinez, Leyi Lin, Jason M. Blaylock, Rafael A. De La Barrera, Alan L. Rothman, J. Robert Putnak, Kenneth H. Eckels, Stephen J. Thomas, Richard G. Jarman, Jeffrey R. Currier
Publikováno v:
mSphere, Vol 5, Iss 1 (2020)
ABSTRACT Dengue is the most prevalent arboviral disease afflicting humans, and a vaccine appears to be the most rational means of control. Dengue vaccine development is in a critical phase, with the first vaccine licensed in some countries where deng
Externí odkaz:
https://doaj.org/article/9a70ddf949f2464fbfa4032091e25a8f
Autor:
Olivia Goethals, Suzanne J. F. Kaptein, Bart Kesteleyn, Jean-François Bonfanti, Liesbeth Van Wesenbeeck, Dorothée Bardiot, Ernst J. Verschoor, Babs E. Verstrepen, Zahra Fagrouch, J. Robert Putnak, Dominik Kiemel, Oliver Ackaert, Roel Straetemans, Sophie Lachau-Durand, Peggy Geluykens, Marjolein Crabbe, Kim Thys, Bart Stoops, Oliver Lenz, Lotke Tambuyzer, Sandra De Meyer, Kai Dallmeier, Michael K. McCracken, Gregory D. Gromowski, Wiriya Rutvisuttinunt, Richard G. Jarman, Nicos Karasavvas, Franck Touret, Gilles Querat, Xavier de Lamballerie, Laurent Chatel-Chaix, Gregg N. Milligan, David W. C. Beasley, Nigel Bourne, Alan D. T. Barrett, Arnaud Marchand, Tim H. M. Jonckers, Pierre Raboisson, Kenny Simmen, Patrick Chaltin, Ralf Bartenschlager, Willy M. Bogers, Johan Neyts, Marnix Van Loock
Publikováno v:
Nature. 615:678-686
Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million1 with annually around 10,000 deaths2. However, no antiviral drugs are available for the treatment or prophylaxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8c0a4183f19bf33ac0d110d21b457f
https://doi.org/10.1038/s41586-023-05790-6
https://doi.org/10.1038/s41586-023-05790-6
Autor:
Michael K McCracken, Gregory D Gromowski, Lindsey S Garver, Brad A Goupil, Kathryne D Walker, Heather Friberg, Jeffrey R Currier, Wiriya Rutvisuttinunt, Kevin L Hinton, Rebecca C Christofferson, Christopher N Mores, Yannick Vanloubbeeck, Clarisse Lorin, Marie-Pierre Malice, Stephen J Thomas, Richard G Jarman, David W Vaughn, J Robert Putnak, Lucile Warter
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 14, Iss 4, p e0008191 (2020)
Dengue virus (DENV) is transmitted by infectious mosquitoes during blood-feeding via saliva containing biologically-active proteins. Here, we examined the effect of varying DENV infection modality in rhesus macaques in order to improve the DENV nonhu
Externí odkaz:
https://doaj.org/article/9c74002c80054d2faa4b9ece61db7f6e
Autor:
J. Robert Putnak, Wiriya Rutvisuttinunt, Yannick Vanloubbeeck, David W. Vaughn, Marie-Pierre Malice, Clarisse Lorin, Brad A. Goupil, Heather Friberg, Richard G. Jarman, Kathryne D. Walker, Jeffrey R. Currier, Christopher N. Mores, Lucile Warter, Rebecca C. Christofferson, Gregory D. Gromowski, Lindsey S. Garver, Michael K. McCracken, Kevin L. Hinton, Stephen J. Thomas
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 14, Iss 4, p e0008191 (2020)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Dengue virus (DENV) is transmitted by infectious mosquitoes during blood-feeding via saliva containing biologically-active proteins. Here, we examined the effect of varying DENV infection modality in rhesus macaques in order to improve the DENV nonhu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f21c5142180257b41d3b32ff2657c7
https://doaj.org/article/9c74002c80054d2faa4b9ece61db7f6e
https://doaj.org/article/9c74002c80054d2faa4b9ece61db7f6e
Autor:
J. Robert Putnak, Jason M. Blaylock, Luis J. Martinez, Jeffrey R. Currier, Leyi Lin, Alan L. Rothman, Rafael De La Barrera, Richard G. Jarman, Stephen J. Thomas, Kenneth H. Eckels, Heather Friberg
Publikováno v:
mSphere, Vol 5, Iss 1 (2020)
mSphere, Vol 5, Iss 1, p e00671-19 (2020)
mSphere
mSphere, Vol 5, Iss 1, p e00671-19 (2020)
mSphere
Dengue is a tropical disease transmitted by mosquitoes, and nearly half of the world’s population lives in areas where individuals are at risk of infection. Several vaccines for dengue are in development, including one which was recently licensed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de0f904d4172f9b122405ae41cebe5b
https://journals.asm.org/doi/10.1128/mSphere.00671-19
https://journals.asm.org/doi/10.1128/mSphere.00671-19
Autor:
Jean-François Toussaint, Rawiwan Imerbsin, Bruce L. Innis, Lucile Warter, Benoît Baras, Rafael De La Barrera, Stefan Fernandez, Kenneth H. Eckels, Richard G. Jarman, Pascale Festraets, Alexander C. Schmidt, Marie-Pierre Malice, Sally Mossman, Stephen J. Thomas, J. Robert Putnak
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
The immunogenicity and protective efficacy of a candidate tetravalent dengue virus purified inactivated vaccine (TDENV PIV) formulated with alum or an Adjuvant System (AS01, AS03 tested at three different dose levels, or AS04) was evaluated in a 0, 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6b628ceca39e627adb48f5f4cb20755
http://europepmc.org/articles/PMC4385761
http://europepmc.org/articles/PMC4385761
Autor:
Michelle Liu, Kenneth H. Eckles, Matthew C. Wise, Heather Friberg, Peter Abbink, Rafael De La Barrera, Bridget S. Lewis, Stephen J. Thomas, Lindsey S. Garver, Mark Milazzo, Dan H. Barouch, Kayvon Modjarrad, David Jetton, Jeffrey R. Currier, Anna B. Mullins, Michael K. McCracken, Richard G. Jarman, J. Robert Putnak, Gregory D. Gromowski, Nelson L. Michael, Xiaoxu Lin, Michael R. Boyd
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 13, Iss 8, p e1006487 (2017)
PLoS Pathogens, Vol 13, Iss 8, p e1006487 (2017)
Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the correlation between in vitro and in vivo findings is not well charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3de9176eed0c6bf10f9a8a0cb2b2d29
http://europepmc.org/articles/PMC5542404
http://europepmc.org/articles/PMC5542404
Autor:
Stephen J. Thomas, Robert R. Edelman, Dennis Cunningham, Niranjan Kanesa-thasan, J. Robert Putnak, Judith G Perry, Kenneth H. Eckels, Bruce L. Innis, Steven S. Wasserman, Wellington Sun, David W. Vaughn
Publikováno v:
Human Vaccines. 5:33-40
Sixteen dose formulations of our live-attenuated tetravalent dengue virus vaccines (TDV) were previously evaluated for safety and immunogenicity. Two of the sixteen candidate TDV formulations (Formulations 13 and 14) were selected for further evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::483e62da432b1b16a281ac6c3592696c
https://doi.org/10.4161/hv.5.1.6348
https://doi.org/10.4161/hv.5.1.6348
Autor:
David W. Vaughn, Bruce L. Innis, Stephen J. Thomas, Ananda Nisalak, Timothy P. Endy, Kenneth H. Eckels, Montip Gettayacamin, Wellington Sun, J. Robert Putnak
Publikováno v:
The Journal of Infectious Diseases. 193:1658-1665
Rhesus monkeys develop viremia after dengue virus (DENV) inoculation and have been used as an animal model to study DENV infection and DENV vaccine candidates. We evaluated, in this model, the protective efficacy of a live attenuated tetravalent DENV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da6bb9afbf80c90a4f17e40ee128783
https://doi.org/10.1086/503372
https://doi.org/10.1086/503372
Autor:
Richard G. Jarman, Monika Simmons, Leyi Lin, Luis J. Martinez, Arthur Lyons, Jeffrey R. Currier, Heather Friberg, Kenneth H. Eckels, Janine R. Danko, Nimfa Teneza-Mora, Kristen M. Bauer, Jason M. Blaylock, Stephen J. Thomas, Rafael De La Barrera, J. Robert Putnak
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flaviviru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::667fb5e52234652d0acfc2feb379cdd6
https://pubmed.ncbi.nlm.nih.gov/26149862
https://pubmed.ncbi.nlm.nih.gov/26149862